摘要
目的 研究CD44V6基因蛋白与非小细胞肺癌(NSCLC)临床病理特征的关系。方法 用S-P免疫组化检测74例NSCLC CD44V6基因蛋白的表达。结果 CD44V6总的阳性表达率为44.6％(33/74),阳性表达与淋巴结有无癌转移、PTNM分期显著相关(P<0.01),与患者3年生存期呈负相关(P<0.05),与细胞的分化程度、年龄、性别均未见显著相关(P>0.05)。结论 CD44V6过表达与NSCLC的预后有密切关系,可作为临床评估、预测肿瘤转移潜能和预后的指标。
Objective To study the relation between expression of CD44V6 protein and the clinical pathological characteristics of non-small cell lung cancer (NSCLC) .Methods Expression of CD44V6 protein was examined in 74 NSCLC samples by immunohistochemistry. Results The positive rate of CD44V6 expression in NSCLC was 44.6% (33/74). the positive rate of CD44V6 expression was significantly higher in NSCLC with lymph node metastasis (63.3%) than that without lymph node metastasis(31.8%, P< 0.01) .In stage I + II patients (30.0 % ) and in stage III + IV patients (59.1 % ), a highly significant difference existed between the two groups ( P < 0.05). The expression of CD44V6 had a negative correlation with the 3-year survival rate ( P < 0.05), but no correlation with cell differention, age, and sex of the patients ( P > 0. 05) . Conclusion Overexpression of CD44V6 may have close relation to prognosis of the patient with NSCLC, can be used to predict metastasis and prognosis of NSCLC.
出处
《中国肿瘤临床与康复》
2003年第5期393-394,共2页
Chinese Journal of Clinical Oncology and Rehabilitation
